Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Article  CAS  PubMed  Google Scholar 

Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol. 2013;31:4445–52.

Article  CAS  PubMed  Google Scholar 

Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338–45.

Article  CAS  PubMed  Google Scholar 

Renovanz M, Kim EL. Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Front Oncol. 2014;4:142.

Article  PubMed  PubMed Central  Google Scholar 

Cioce M, Sacconi A, Pass HI, Canino C, Strano S, Blandino G, et al. Insights into intra-tumoral heterogeneity: transcriptional profiling of chemoresistant MPM cell subpopulations reveals involvement of NFkB and DNA repair pathways and contributes a prognostic signature. Int J Mol Sci. 2021;22:12071.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hajjaji N, Abbouchi M, Nguyen LA, Charles S, Leclercq S, Bertin D, et al. A novel proteomic mass spectrometry-based approach to reveal functionally heterogeneous tumor clones in breast cancer metastases and identify clone-specific drug targets. J Clin Oncol. 2020;38:e13063.

Article  Google Scholar 

Ho SWT, Tan P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Sci. 2019;110:3405–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 2018;8:37–48.

Article  CAS  PubMed  Google Scholar 

Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, et al. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut. 2021;70:464–75.

Article  CAS  PubMed  Google Scholar 

Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, et al. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. Ann Oncol. 2019;30:1254–64.

Article  CAS  PubMed  Google Scholar 

Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013;49:1448–57.

Article  CAS  PubMed  Google Scholar 

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2019;22:518–25.

Article  CAS  PubMed  Google Scholar 

Balluff B, Frese CK, Maier SK, Schone C, Kuster B, Schmitt M, et al. De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. J Pathol. 2015;235:3–13.

Article  CAS  PubMed  Google Scholar 

Chao J, Bedell V, Lee J, Li MS, Chu P, Yuan YC, et al. Association between spatial heterogeneity within nonmetastatic gastroesophageal adenocarcinomas and survival. JAMA Netw Open. 2020;3:e203652.

Article  PubMed  PubMed Central  Google Scholar 

Abdelmoula WM, Balluff B, Englert S, Dijkstra J, Reinders MJ, Walch A, et al. Data-driven identification of prognostic tumor subpopulations using spatially mapped t-SNE of mass spectrometry imaging data. Proc Natl Acad Sci USA. 2016;113:12244–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Z, Bao C, Jiang L, Wang S, Wang K, Lu C, et al. When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective. Front Oncol. 2022;12:1054233.

Article  CAS  PubMed  Google Scholar 

Wei S, Liu L, Zhang J, Bowers J, Gowda GA, Seeger H, et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 2013;7:297–307.

Article  CAS  PubMed  Google Scholar 

Yang K, Zhang F, Han P, Wang ZZ, Deng K, Zhang YY, et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for colorectal cancer. Metabolomics. 2018;14:110.

Article  PubMed  Google Scholar 

Wang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, et al. Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. Clin Cancer Res. 2022;28:2865–77.

Article  CAS  PubMed  Google Scholar 

Kunzke T, Holzl FT, Prade VM, Buck A, Huber K, Feuchtinger A, et al. Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer. Clin Transl Med. 2021;11:e547.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prade VM, Kunzke T, Feuchtinger A, Rohm M, Luber B, Lordick F, et al. De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry. Mol Metab. 2020;36:100953.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balluff B, Rauser S, Ebert MP, Siveke JT, Hofler H, Walch A. Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. Gastroenterology. 2012;143:544–9.e2.

Article  CAS  PubMed  Google Scholar 

Aichler M, Walch A. MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015;95:422–31.

Article  CAS  PubMed  Google Scholar 

Shen J, Sun N, Wang J, Zens P, Kunzke T, Buck A, et al. Patterns of carbon-bound exogenous compounds impact disease pathophysiology in lung cancer subtypes in different ways. ACS Nano. 2023;17:16396–411.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Addie RD, Balluff B, Bovee JV, Morreau H, McDonnell LA. Current state and future challenges of mass spectrometry imaging for clinical research. Anal Chem. 2015;87:6426–33.

Article  CAS  PubMed  Google Scholar 

Oppenheimer SR, Mi D, Sanders ME, Caprioli RM. Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. J Proteome Res. 2010;9:2182–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulbe H, Klein O, Wu Z, Taube ET, Kassuhn W, Horst D, et al. Discovery of prognostic markers for early-stage high-grade serous ovarian cancer by MALDI-imaging. Cancers. 2020;12:2000.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods. 2007;4:828–33.

Article  CAS  PubMed  Google Scholar 

Shen J, Sun N, Zens P, Kunzke T, Buck A, Prade VM, et al. Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients. Cancer Commun. 2022;42:517–35.

Article  Google Scholar 

Deininger SO, Ebert MP, Futterer A, Gerhard M, Rocken C. MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. J Proteome Res. 2008;7:5230–6.

Article  CAS  PubMed  Google Scholar 

Jones EA, Schmitz N, Waaijer CJ, Frese CK, van Remoortere A, van Zeijl RJ, et al. Imaging mass spectrometry-based molecular histology differentiates microscopically identical and heterogeneous tumors. J Proteome Res. 2013;12:1847–55.

Article  CAS  PubMed  Google Scholar 

Wang J, Sun N, Kunzke T, Shen J, Zens P, Prade VM, et al. Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma. NPJ Precis Oncol. 2023;7:114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haffner I, Schierle K, Raimundez E, Geier B, Maier D, Hasenauer J, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39:1468–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ly A, Buck A, Balluff B, Sun N, Gorzolka K, Feuchtinger A, et al. High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. Nat Protoc. 2016;11:1428–43.

Article  PubMed